Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported strong financial results for Q4 and full year 2024. Q4 revenues reached $186.5 million with GAAP net income of $38.0 million ($0.74 per share) and adjusted non-GAAP net income of $47.2 million ($0.92 per share).
For the full year 2024, the company achieved net revenues of $732.0 million, GAAP net income of $159.5 million ($3.06 per share), and adjusted non-GAAP net income of $200.8 million ($3.86 per share). Notable achievements include exceeding $100 million in annual sales for Primatene MIST and BAQSIMI showing 12% factory sales growth compared to Q4 2023.
The company's pipeline includes four ANDAs targeting products with >$2 billion market size, four biosimilar products targeting >$7 billion market size, and two generic products targeting >$1.3 billion market size. Operating cash flow for 2024 was $213.4 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its Q4 2024 earnings release for February 27, 2025, after market close. The company will host a conference call at 2:00 p.m. Pacific Time to discuss financial results.
Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also sells insulin API products, with most finished products distributed through group purchasing organizations and drug wholesalers for hospital or urgent care clinical settings.
The company highlights its transition towards high-value and high-growth areas market, including the integration of BAQSIMI®, and its focus on branded products, proprietary products, and biosimilars.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO and President Jack Zhang, along with CFO Bill Peters, will deliver a presentation on Wednesday, January 15th, 2025, at 11:15 am PST.
The presentation will be accessible through a webcast on Amphastar's website at http://ir.amphastar.com. Interested parties can access the webcast recording for 30 days following the presentation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Bill Peters, CFO, and Dan Dischner, SVP of Corporate Communication, will engage in an analyst-moderated fireside chat on December 4th, 2024 at 11:30 am EST. The presentation will be accessible through Amphastar's website at ir.amphastar.com, with the webcast remaining available for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the Jefferies London Healthcare Conference. CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will engage in an analyst-moderated fireside chat on Wednesday, November 20, 2024, at 3:30 pm GMT. The presentation will be accessible through Amphastar's website at http://ir.amphastar.com, with the webcast remaining available for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q3 2024 financial results with net revenues of $191.2 million, up 6% year-over-year. The company achieved GAAP net income of $40.4 million ($0.78 per share) and adjusted non-GAAP net income of $49.6 million ($0.96 per share). BAQSIMI® contributed significantly with $40.4 million in direct sales, while Primatene MIST® sales increased 5% to $26.1 million. The Board authorized a $50 million increase to the share buyback program. Operating cash flow for the first nine months was $184.4 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its third quarter 2024 earnings release and conference call for November 6, 2024. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time. Investors can access the call via toll-free number 877-407-0989 or international number 201-389-0921. The call will also be available through the company's website, with a replay accessible within 24 hours after the live conference.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the 2024 Wells Fargo Healthcare Conference. Key details include:
- CFO Bill Peters and EVP Tony Marrs will engage in a fireside chat
- The event is scheduled for Thursday, September 5, 2024, at 10:15 am EST
- Access to the presentation will be available on Amphastar's website at http://ir.amphastar.com
- The webcast will remain accessible for 30 days following the presentation
This participation underscores Amphastar's commitment to engaging with investors and sharing insights about the company's operations and future prospects in the pharmaceutical industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported strong financial results for Q2 2024. Key highlights include:
- Net revenues of $182.4 million, up 25% year-over-year
- GAAP net income of $37.9 million, or $0.73 per share
- Adjusted non-GAAP net income of $48.7 million, or $0.94 per share
The company's performance was driven by:
- BAQSIMI® sales of $30.9 million
- Epinephrine sales increase of 67% to $27.9 million
- Primatene MIST® sales growth of 38% to $22.9 million
Gross profit margin improved to 52.2% from 49.9% in Q2 2023. The company's pipeline includes 3 ANDAs, 3 biosimilars, and 4 generic products in development, targeting markets worth over $13 billion.
Amphastar Pharmaceuticals (NASDAQ:AMPH), a bio-pharmaceutical company specializing in technically challenging generic and proprietary injectable, inhalation, and intranasal products, has announced its second quarter 2024 earnings release and conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Wednesday, August 7, 2024. A conference call to discuss these results is scheduled for 2:00 p.m. Pacific Time on the same day.
Investors can access the call by dialing 877-407-0989 (toll-free) or 201-389-0921 (international). The call will also be available via webcast on the company's website, with a replay accessible within 24 hours after the live call ends. Amphastar's products are primarily used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.
FAQ
What is the current stock price of Amphastar Pharma (AMPH)?
What is the market cap of Amphastar Pharma (AMPH)?
